Katherine F. Roby

Immunology and MicrobiologyMedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model”.

The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model

BMC Cancer(2025)10.1186/s12885-025-13640-z

N/A

0.104DataRank · unranked

1 citations

Katherine F. Roby, Harsh B. Pathak, Andrew K. Godwin, Sumedha Gunewardena, Dineo Khabele +1 more

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.01.038

N/A

0DataRank · unranked

42 citations

Andrew J. Wilson, Jeff Hirst, Katherine F. Roby, Oluwole Fadare, Marta A. Crispens +3 more

Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer

Cell Death and Disease(2024)10.1038/s41419-024-06717-3

N/A

0DataRank · unranked

5 citations

Prasad Dandawate, Sumedha Gunewardena, Obdulia Covarrubias‐Zambrano, Katherine F. Roby, Dineo Khabele +8 more